Results 101 to 110 of about 8,795,233 (257)
Background and objective The proportion of patients carrying driver gene mutations is notably high among individuals with non-small cell lung cancer (NSCLC) in China.
Zihan WEI +3 more
doaj +1 more source
Contemporary update on neoadjuvant therapy for bladder cancer.
Administration of neoadjuvant chemotherapy preceding radical cystectomy in patients with bladder cancer remains a matter of debate. Results of prospective, randomized studies have demonstrated an overall absolute survival benefit of 5% at 5 years ...
George N. Thalmann +3 more
core +1 more source
Targeting the YAP‐BST2 Axis Overcomes Intrinsic Anti‐PD‐1 Resistance in Metastatic Gastric Cancer
Concurrent YAP hyperactivation and Tp53 loss in Atp4b‐expressed parietal cell lineage drives gastric cancer initiation, multi‐organ metastasis, and intrinsic resistance to anti‐PD‐1 therapy. BST2 emerges as a direct YAP‐TEAD transcriptional target that engages PIRA2 on myeloid cells to establish an immunosuppressive microenvironment.
Weihong Zhang +17 more
wiley +1 more source
High‐density type I collagen promotes glutamine (Gln) accumulation–related ferroptosis of TNBC cells via the spermidine/spermine N1‐acetyltransferase 1 (SAT1)‐ argininosuccinate synthase (ASS1) signaling pathway, thus depriving immune cells of Gln supply and inducing IFN‐γ+ CD8+ T cell exhaustion in the TME.
Jinyan Wang +11 more
wiley +1 more source
This long‐term follow‐up study determined survival rates in a Swedish national cohort of 417 patients with breast cancer who all had neoadjuvant systemic therapy (NAST). Sentinel lymph node biopsy (SLNB) was performed before NAST in clinically node‐negative and after NAST in clinically node‐positive patients.
L. Zetterlund +4 more
wiley +1 more source
Background: The treatment of locally advanced rectal cancer (LARC) has steadily progressed over the past four decades, with recent focus shifting towards total neoadjuvant therapy (TNT).
Philipp Schredl +25 more
core +1 more source
An engineered allosteric biosensor (UUU‐DZ‐tFNA) was developed, in which UDG specifically recognizes and activates a DNAzyme to achieve signal cycle amplification in a sequentially activatable mode. UUU‐DZ‐tFNA achieves in situ UDG detection across multiple biological levels and facilitates risk stratification and drug resistance monitoring of NB ...
Yaqing Lu +10 more
wiley +1 more source
All patients operated for oesophageal cancer in Sweden from 2013 to April 2018 were identified, and 246 patients were recruited to this population‐based nationwide Swedish study. The results show that longitudinal health‐related quality of life after minimally invasive oesophagectomy was similar to that of the open surgical approach.
F. Klevebro +4 more
wiley +1 more source
This study reveals that large tumors secrete more chemokine CXCL3, which recruits immunosuppressive neutrophils to the periphery, thereby impairing the activation and memory of systemic tumor‑reactive CD8+ T cells. CXCL3 antagonism restores systemic immune memory and enhances the antitumor efficacy of anti‑PD‑1 therapy, offering a potential strategy to
Ji Wang +15 more
wiley +1 more source
This study identifies reduced taurine availability as a mediator of intermittent fasting in colorectal cancer and shows that taurine interacts with GRP78 to maintain PERK abundance post‐transcriptionally. It further shows that taurine depletion destabilizes PERK, induces immunogenic paraptosis, remodels the tumor microenvironment toward a CD8+ T cell ...
Baohui Song +11 more
wiley +1 more source

